Jon Tosh
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non-Small Cell Lung Cancer Harboring Mesenchymal-Epithelial Transition Exon 14 Skipping.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: June 20, 2022
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Journal: Expert review of hematology
Published: September 01, 2021
Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States.
Journal: Journal of medical economics
Published: June 15, 2021
Health Economic Analysis of Access Site Practice in England During Changes in Practice: Insights From the British Cardiovascular Interventional Society.
Journal: Circulation. Cardiovascular quality and outcomes
Published: December 04, 2017
A cost-effectiveness analysis of condom distribution programmes for the prevention of sexually transmitted infections in England.
Journal: Journal of epidemiology and community health
Published: January 30, 2017
Constrained Optimization Methods in Health Services Research-An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: January 17, 2017
Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Journal: Health technology assessment (Winchester, England)
Published: December 07, 2016
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Journal: Health technology assessment (Winchester, England)
Published: May 04, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026